|
||||||||||
---|---|---|---|---|---|---|---|---|---|---|
|
|
The vector sequence has been compiled using the information from sequence databases, published literature, and other sources, together with partial sequences obtained by Evrogen. This vector has not been completely sequenced. |
|||||||||||||||||||||||||||||||||||||||||||||||||
Download
|
|
Nhe I | Bgl II | Sac I | Hind III | EcoR I | Sal I | Kpn I | Apa I* | BamH I | Age I | TurboGFP | |||||||||||||||||||
Afe I | Xho I | Pst I* | Sac II | Nco I* | |||||||||||||||||||||||||
GCT | A.GC | G.CT | A.CCG.GAC.TC | A.GAT. | CT | C. | GAG. | CTC. | AAG.CTT. | C | GA.ATT. | C | TG.CA | G. | TCG.AC | G.GTA. | CC | G.C | GG. | G | CC.C | G | G.G | AT.CC | A.CCG.GT | C.GCC.A | CC. | ATG.G | AG.AGC |
* – not unique site.
pTurboGFP-N is a mammalian expression vector encoding green fluorescent protein TurboGFP (see reporter description). The vector allows generation of fusions to the TurboGFP N-terminus and expression of TurboGFP fusions or TurboGFP alone in eukaryotic (mammalian) cells.
TurboGFP codon usage is optimized for high expression in mammalian cells (humanized) [Haas et al., 1996]. To increase mRNA translation efficiency, Kozak consensus translation initiation site is generated upstream of the TurboGFP coding sequence [Kozak, 1987]. Multiple cloning site (MCS) is located between PCMV IE and TurboGFP coding sequence.
The vector backbone contains immediate early promoter of cytomegalovirus (PCMV IE) for protein expression, SV40 origin for replication in mammalian cells expressing SV40 T-antigen, pUC origin of replication for propagation in
SV40 early promoter (PSV40) provides neomycin resistance gene (Neor) expression to select stably transfected eukaryotic cells using G418. Bacterial promoter (P) provides kanamycin resistance gene expression (Kanr) in
Generation of TurboGFP fusion proteins
A localization signal or a gene of interest can be cloned into MCS of the vector. It will be expressed as a fusion to the TurboGFP N-terminus when inserted in the same reading frame as TurboGFP and no in-frame stop codons are present. The inserted sequence should contain an initiating ATG codon. TurboGFP-tagged fusions retain fluorescent properties of the native protein allowing fusion localization in vivo. Unmodified vector will express TurboGFP when transfected into eukaryotic (mammalian) cells.
Note: The plasmid DNA was isolated from dam+-methylated
Expression in mammalian cells
pTurboGFP-N vector can be transfected into mammalian cells by any known transfection method. CMV promoter provides strong, constitutive expression of TurboGFP or its fusions in eukaryotic cells. If required, stable transformants can be selected using G418 [Gorman, 1985].
Propagation in
Suitable host strains for propagation in
Location of features
PCMV IE: 1-589
Enhancer region: 59-465
TATA box: 554-560
Transcription start point: 583
MCS: 591-671
TurboGFP
Kozak consensus translation initiation site: 672-682
Start codon (ATG): 679-681
Stop codon: 1375-1377
SV40 early mRNA polyadenylation signal
Polyadenylation signals: 1531-1536 & 1560-1565
mRNA 3' ends: 1569 & 1581
f1 single-strand DNA origin: 1628-2083
Bacterial promoter for expression of Kanr gene
-35 region: 2145-2150
-10 region: 2168-2173
Transcription start point: 2180
SV40 origin of replication: 2424-2559
SV40 early promoter
Enhancer (72-bp tandem repeats): 2257-2328 & 2329-2400
21-bp repeats: 2404-2424, 2425-2445 & 2447-2467
Early promoter element: 2480-2486
Major transcription start points: 2476, 2514, 2520 & 2525
Kanamycin/neomycin resistance gene
Neomycin phosphotransferase coding sequences:
Start codon (ATG): 2608-2610
Stop codon: 3400-3402
G->A mutation to remove Pst I site: 2790
C->A (Arg to Ser) mutation to remove BssH II site: 3136
Herpes simplex virus (HSV) thymidine kinase (TK) polyadenylation signal
Polyadenylation signals: 3638-3643 & 3651-3656
pUC plasmid replication origin: 3987-4630
TurboGFP-related materials (also referred to as "Products") are intended for research use only. The Products are covered by U.S. Pat. 7,678,893; European Pat. 1576157; and other Evrogen Patents and/or Patent applications pending. By use of these Products, you accept the terms and conditions of the applicable Limited Use Label License.
Copyright 2002-2023 Evrogen. All rights reserved. Evrogen JSC, 16/10 Miklukho-Maklaya str., Moscow, Russia, Tel +7(495)988-4084, Fax +7(495)988-4085, e-mail:evrogen@evrogen.com |